AIM ImmunoTech Files 8-K on Shareholder Votes and Financials

Ticker: AIM · Form: 8-K · Filed: May 1, 2025 · CIK: 946644

Sentiment: neutral

Topics: corporate-governance, financials, filing

TL;DR

AIM ImmunoTech filed an 8-K on April 30, 2025, covering shareholder votes and financials.

AI Summary

AIM ImmunoTech Inc. filed an 8-K on May 1, 2025, reporting on matters submitted to a vote of security holders and financial statements as of April 30, 2025. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and operates in the biological products sector.

Why It Matters

This filing provides updates on corporate governance and financial status, which are crucial for investors to assess the company's operational health and strategic direction.

Risk Assessment

Risk Level: low — This is a routine filing reporting on standard corporate actions and financial statements, not indicating any immediate material changes or risks.

Key Players & Entities

FAQ

What specific matters were submitted to a vote of security holders?

The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.

What is the primary business of AIM ImmunoTech Inc.?

AIM ImmunoTech Inc. operates in the Biological Products (no diagnostic substances) sector, SIC code 2836.

When was AIM ImmunoTech Inc. formerly known as?

AIM ImmunoTech Inc. was formerly known as HEMISPHERX BIOPHARMA INC.

What is the principal executive office address for AIM ImmunoTech Inc.?

The principal executive offices are located at 2117 SW Highway 484, Ocala, FL 34473.

What is the fiscal year end for AIM ImmunoTech Inc.?

The fiscal year end for AIM ImmunoTech Inc. is December 31.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 1, 2025 regarding AIM ImmunoTech Inc. (AIM).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing